Form 10-Q/A
---------------------------------------------------------------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q/A
Amendment No. 1 to Form 10-Q
---------------------------------------------------------------------------------------------------------------------------------------
{X} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2001
Commission File No. 0-19131
MedImmune, Inc.
(Exact name of registrant as specified in its charter)
Delaware 52-1555759
(State or other jurisdiction of (I. R. S. Employer
incorporation or organization) Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file
such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
As of September 30, 2001, 214,044,267 shares of Common Stock, par value $0.01 per share, were outstanding.
EXPLANATORY NOTE
This quarterly report on Form 10-Q/A for the quarterly period ended September 30, 2001 is being filed solely to amend the list of
exhibits included in Item 6 therein and to re-file a new version of Exhibit 10.129. Exhibit 10.129 was previously and is hereby
filed pursuant to a confidential treatment request filed with the Securities and Exchange Commission. The Form 10-Q/A constitutes
Amendment No. 1 to MedImmune, Inc.'s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2001.
MEDIMMUNE, INC.
PART II
OTHER INFORMATION
Item 6. Exhibits and reports on Form 8-K
(a) Exhibits:
10.129 Amendment No. 3 to Distribution and Marketing Collaboration Agreement between MedImmune Oncology,
Inc. and ALZA Corporation.*
(b) Reports on Form 8-K:
Report Date Event Reported
----------- --------------
9/11/01 MedImmune Accelerates Reacquisition
of U.S. Rights to Ethyol From ALZA
* Confidential treatment has been requested. The copy filed as an exhibit omits the information subject to the confidentiality
request. Such information has been filed separately with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.
MEDIMMUNE, INC.
(Registrant)
/s/: Gregory S. Patrick
Date: December 14, 2001 Gregory S. Patrick
Senior Vice President and Chief Financial Officer